Get the Stockscreener App
44.79
1.99%
-0.91
After Hours:
45.00
0.21
+0.47%
Supernus Pharmaceuticals Inc stock is traded at $44.79, with a volume of 744.19K.
It is down -1.99% in the last 24 hours and down -13.18% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$45.70
Open:
$46.23
24h Volume:
744.19K
Relative Volume:
0.89
Market Cap:
$2.51B
Revenue:
$665.13M
Net Income/Loss:
$64.50M
P/E Ratio:
39.15
EPS:
1.1442
Net Cash Flow:
$185.87M
1W Performance:
+0.79%
1M Performance:
-13.18%
6M Performance:
+34.91%
1Y Performance:
+24.00%
1-Day Range:
$44.76
$46.47
1-Week Range:
$44.05
$46.47
52-Week Range:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
44.79 | 2.62B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Why Supernus Pharmaceuticals Inc. stock could benefit from AI revolutionQuarterly Trade Summary & Growth Focused Entry Point Reports - newser.com
Understanding the Setup: (SUPN) and Scalable Risk - news.stocktradersdaily.com
How Supernus Pharmaceuticals Inc. stock benefits from tech adoption2025 Pullback Review & Real-Time Volume Analysis Alerts - newser.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.Sell Signal & Expert Approved Trade Ideas - newser.com
Statistical indicators supporting Supernus Pharmaceuticals Inc.’s strengthJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Measuring Supernus Pharmaceuticals Inc.’s beta against major indices2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Is Supernus Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Raising 2025 Revenue Guidance Despite Net Losses - simplywall.st
Supernus at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com Australia
SUPN: Strong CNS portfolio growth, supply challenges for Onapgo, and active business development focus - TradingView
What analysts say about Supernus Pharmaceuticals Inc stockTechnical Breakout Signals & Free Powerful Profit Generation - earlytimes.in
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.2025 Macro Impact & Technical Confirmation Alerts - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementJobs Report & Weekly Momentum Stock Picks - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsWeekly Investment Summary & Community Consensus Stock Picks - newser.com
Why Supernus Pharmaceuticals Inc. stock remains undervaluedEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London - The Manila Times
Supernus (NASDAQ: SUPN) fireside chat Nov. 17 at 9:30 a.m. EST; webcast available - Stock Titan
5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2025 Earnings Call Transcript - MSN
The Technical Signals Behind (SUPN) That Institutions Follow - news.stocktradersdaily.com
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.17%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):